Developing Cell Lines for COVID-19 Vaccine Candidates

Dyadic and Frederick National Laboratory to develop cell lines for COVID-19 vaccine candidates using Dyadic's C1 gene expression platform

Dyadic is focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that it was selected by the Frederick National Laboratory to engineer its patented and proprietary C1 cell lines to produce a number of COVID-19 vaccine candidates which will be utilized by the Vaccine Research Center (VRC) part of the National Institute of Allergy and Infectious Diseases (NIAID), at the National Institutes of Health.
"We are proud that our C1 technology has the potential to support the Vaccine Research Center COVID-19 vaccine development program by engineering innovative high yield C1 fungal cell lines to rapidly produce candidate vaccines with increased immunogenicity and attractive manufacturing properties." said Mark Emalfarb, Dyadic's Chief Executive Officer.

Mr. Emalfarb also commented, "In addition, we are grateful to be able to  also work together with the US, EU, Israel, and are in other discussions with governmental agencies, biotech/biopharma companies, and funding organizations to apply our industrially proven hyper productive C1 gene expression platform by helping to address the immediate coronavirus outbreak and be better prepared for future infectious diseases, pandemic, and epidemic outbreaks. We hope to turn this unfortunate situation into an opportunity to advance biopharmaceutical manufacturing to help speed development, lower the cost and improve the performance of biologic vaccines and drugs such as insulin, seasonal flu and other vaccines and antibodies to make healthcare more accessible and affordable to patients globally."


Recent Issues